Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (Cosmofer) in patients with chronic kidney disease

American Journal of Nephrology

Volumn 35, Issue 1, 2012, Pages 69-74

  Cooke, M ^a   Lamplugh, A ^a   Naudeer, S ^a   Edey, M ^a   Bhandari, S ^a  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Iron

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON DEXTRAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FLUSHING; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RESPIRATORY DISTRESS; SHIVERING; SHOCK; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THORAX PAIN; URTICARIA;

ADOLESCENT; ADULT; AGED; DEXTRANS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, STATISTICAL; MOLECULAR WEIGHT; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 83755206829     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000334877     Document Type: Article

References (31)

1. Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112-119.
2. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anaemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. J Am Soc Nephrol 2002; 13: 504-510. (Pubitemid 34106294)
3. Department of Health: The National Service Framework for Renal Service (Part 2, Chronic Kidney Disease). London, Department of Health, 2005.
4. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S, European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2):1-47.
5. NICE Guidelines: Anaemia management in people with chronic kidney disease (CKD). Clinical Guidance, CG39, 2006.
6. Bhandari S, Brownjohn A, Turney J: Effective utilization of erythropoietin with intravenous iron therapy. J Clin Pharm Ther 1998; 23: 73-78. (Pubitemid 28380378)
7. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoietin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538. (Pubitemid 30115083)
8. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients with erythropoietin. Kidney Int 1996; 50: 1694-1699. (Pubitemid 26364277)
9. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
10. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE investigators: Normalisation of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
11. Pfeffern MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
12. Bhandari S, Naudeer S: Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract 2008; 14: 996-1001.
13. Finch C: Regulators of iron balance in humans. Blood 1994; 84: 1697-1702. (Pubitemid 24286117)
14. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-534. (Pubitemid 26337591)
15. Atalay H, Solak Y, Acar K, Govec N, Turk S: Safety profiles of total dose infusion of lowmolecular- weight iron dextran and highdose iron sucrose in renal patients. Hemodial Int 2011; 15: 374-378.
16. Agarwal R: Nonhematological benefits of iron. Am J Nephrol 2007; 27: 565-571. (Pubitemid 350014943)
17. Bhandari S, Brownjohn AM, Turney JH: Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 3276-3277. (Pubitemid 28534759)
18. Moniem KA, Bhandari S: Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med 2007; 9: 37-42.
19. Ganz T: Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400. (Pubitemid 46193304)
20. Hörl WH: Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 530-531.
21. Mircescu G, Gârneata L, Capusa C, Ursea N: Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-124. (Pubitemid 43057119)
22. Halliwell B, Gutteridge J: Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990; 186: 1-85. (Pubitemid 20279941)
23. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103. (Pubitemid 34701216)
24. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289. (Pubitemid 38670014)
25. Agarwal R, Leehey DJ, Olsen SM, Dahl NV: Proteinuria induced by parenteral iron in chronic kidney disease - a comparative randomised controlled trial. Clin J Am Soc Nephrol 2011; 6: 114-121.
26. Shah SV, Baliga R, Rajapurkar M, Fonseca VA: Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28. (Pubitemid 46053418)
27. Ferinject - Summary of Product Characteristics (SPC) by Syner-Med. http://emc.medicines. org.uk/document.aspx?documentId= 20987.
28. Monofer Core SPC, data on file: Holbaek, Denmark: Pharmacosmos A/S, 2010. http://www.pharmacosmos.com/.
29. Wikström B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL: Iron isomaltoside 1000: a new intravenous iron for treatment of iron deficiency in chronic kidney disease. J Nephrol 2011; 24: 589-596.
30. Tagboto S, Cropper L, Turner J, Pugh-Clarke K: The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care 2009; 35: 18-23.
31. Sinha S, Chiu D, Peebles G, Swoboda P, Kolakkat S, Lamerton E, Fenwick S, Bhandari S, Kalra P: Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients. QJM 2011; 104: 221-230.